Announced
Financials
Tags
biotechnology
Friendly
Single Bidder
Majority
Public
Biotechnology
Acquisition
United States
Pending
Domestic
Private Equity
Synopsis
Athenex, a biopharmaceutical company, agreed to acquire Kuur Therapeutics, developer of cell immunotherapies for the treatment of solid and hematological malignancies, from Schroder, a closed-ended investment company, for $185m. “Kuur’s innovative technology, combined with our TCR program, could propel us into a leadership position in cell therapy. This platform also has the potential to provide synergies with other assets in our pipeline,” Johnson Lau, Athenex CEO.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.